

Vaccination scenarios

12.03.2021 – Conservative and optimistic

12.03.2021


Vaccination scenario

CONSERVATIVE SCENARIO

When do we expect to be able to vaccinate different groups against COVID-19?

VERSION 12. MARCH
THE CALENDAR IS PRELIMINARY AND
WILL BE UPDATED REGULARLY

- This scenario includes the conservative delivery forecasts for Pfizer-BioNTech, Moderna, AstraZeneca and Janssen.
- The figures are uncertain and the scenario gives a preliminary picture.
- The vaccination scenario shows a simplified national average where we assume that the recommended prioritisations are followed and that the municipalities vaccinate at the same rate.



¹ See detailed information on the last page


Vaccination scenario

OPTIMISTIC SCENARIO

When do we expect to be able to vaccinate different groups against COVID-19?

VERSION 12. MARCH
THE CALENDAR IS PRELIMINARY AND
WILL BE UPDATED REGULARLY

- This scenario includes the conservative delivery forecasts for Pfizer-BioNTech, Moderna, AstraZeneca and Janssen.
- The figures are uncertain and the scenario gives a preliminary picture.
- The vaccination scenario shows a simplified national average where we assume that the recommended prioritisations are followed and that the municipalities vaccinate at the same rate.



¹ See detailed information on the last page

Vaccination scenario

Assumptions and background information

VERSION 12 MARCH

For further information about the Coronavirus Immunisation Programme, see <https://www.fhi.no/en/id/vaccines/cvp/>

Assumptions and background information

- Vaccines from AstraZeneca, Pfizer/BioNTech and Moderna are given to people over 18 years.
- Certain risk groups, including people with organ transplants will only be offered mRNA vaccines.
- The size of prioritised groups has been adjusted according to updated figures from the Beredt-C-19 register. This ensures that people are not counted in both an occupational and an age group.
- An assessment is ongoing whether people between the ages of 16 and 18 should be offered vaccination with the available vaccines.
- It is assumed in these scenarios that 380,000 health personnel are prioritised together with people ≥ 85 years of age. Until further notice, it is assumed that approximately 40,000 or more doses are allocated per month for the specialist health service, and that up to 20% of doses sent to municipalities are reserved for health personnel. This is a preliminary assumption and will be assessed on an ongoing basis.
- It is assumed in the scenarios that the municipalities follow prioritisation recommendations and that they vaccinate at the same rate. In practice, there will be variation between the municipalities.
- In the scenarios, it is assumed that 90% of all those who are offered a vaccine take it, and that 95% of these again show up for a second dose. Actual vaccine uptake may differ and will be assessed on an ongoing basis.
- The distribution key changes from 1st April according to NIPH's recommendations. Geographical prioritisation to Oslo, Lørenskog, Fredrikstad, Moss and Sarpsborg introduced from (and including) week 11. ²

Size of prioritised groups³

	<i>Number</i>
Residents in nursing homes	40 000
Health personnel	380 000
85 years and over	115 000
75-84 years	290 000
65-74 years, and 18-64 with underlying diseases and conditions with high risk of severe disease course ³	565 000
55-64 years with underlying diseases and conditions ³	110 000
45-54 years with underlying diseases and conditions ³	100 000
18-44 years with underlying diseases and conditions ³	110 000
55-64 years	415 000
45-54 years	565 000
18-44 years ⁴	1 560 000

Vaccine deliveries (doses) in these scenarios – version 12 March 2021

	<i>December</i>	<i>January</i>	<i>February</i>	<i>March</i>	<i>April</i>	<i>May</i>	<i>June</i>	<i>July</i>
Pfizer-BioNTech ⁴	53	187	210	320	580	560	1 160	700
Moderna		10	30	70	70	140	140	510
AstraZeneca (con-opt)			90	230	140	200	200	200-400
J&J/Janssen					310	310	310	700
Curevax+Novavax (opt)					60	550	210	290

² <https://www.fhi.no/contentassets/1af4c6e655014a738055c79b72396de8/svar-pa-tilleggsoppdrag-til-delleveranse-pa-oppdrag-8-.pdf>

³ Read more about definition of risk groups: [fhi.no/en/id/vaccines/coronavirus-immunisation-programme/who-will-get-coronavirus-vaccine-first/](https://www.fhi.no/en/id/vaccines/coronavirus-immunisation-programme/who-will-get-coronavirus-vaccine-first/)

⁴ Vaccination arrangements for age group 18-44 years are being assessed and not yet fully decided.

Conditions for vaccination scenarios

Changes in conditions for vaccination scenarios

For further information about the Coronavirus Immunisation Programme, see <https://www.fhi.no/en/id/vaccines/cvp/>

- The number of people in the various target groups has changed based on updated figures from NIPH
- The size of priority groups has been adjusted according to updated figures from the Beredt-C-19 register. This ensures that people are not counted as both part of an occupational group and an age group
- The number of health personnel is a total of 380,000 compared to 370,000 previously. This is divided into two groups:
The specialist health service in total: 140,000 and the primary health service in total: 240,000
- Number of vaccines received and distributed has changed as a result of updated figures from vaccine manufacturers
- Conservative scenario includes vaccine types: Pfizer, Moderna, AstraZeneca and J&J. In addition, AstraZeneca is limited to a maximum of 200,000 doses per month in the period April – September
- Optimistic scenario includes the vaccine types: as conservative scenario, plus Curevax and Novavax. In addition, AstraZeneca is limited to a maximum of 200,000 doses per month in the period April – June
- The underlying distribution key has been changed as of week 12
 - The distribution key for mRNA vaccines, as well as J&J, Curevax and Novavax has been changed from «over 65 years» to «over 18 years» plus a geographical priority of 20% to the municipalities: Oslo, Lørenskog, Sarpsborg, Fredrikstad and Moss
 - The distribution key for AstraZeneca has been changed from "under 65 years" to "over 18 years", plus an adjusted distribution of 20% to the municipalities: Oslo, Lørenskog, Sarpsborg, Fredrikstad and Moss
 - For weeks 11 - 13, Moderna doses are used for geographical prioritisation
- Certain high-risk groups over the age of 18 do not receive AstraZeneca
- AstraZeneca doses are not being sent out in weeks 12 and 13, neither dose 1 nor dose 2
- Suspension of AZ for two weeks (weeks 11-12) is assumed not to affect the calendar much for two reasons:
 - 1) Relatively few doses were originally planned to be distributed during these weeks
 - 2) These doses will be distributed in week 13 instead so that the total number of AZ doses distributed remains the same

Changes in conditions for vaccination scenarios

For further information about the Coronavirus Immunisation Programme, see <https://www.fhi.no/en/id/vaccines/cvp/>

- The shift between doses 1 and 2 has been changed to the following number of weeks from week 11 onwards:
 - Pfizer – 6 weeks
 - Moderna – 6 weeks
 - AstraZeneca – 12 weeks
 - Curevax – 6 weeks
 - Novavax – 6 weeks
- The number of weeks between doses 1 and 2 is reduced towards the end of the period in order to complete vaccination of the population groups at an earlier time. This applies to: Pfizer (3 weeks), Moderna (4 weeks) and AstraZeneca (8 weeks)
- A geographical prioritisation of vaccine doses is made until the population group «over 18 years of age» is 95% fully vaccinated in the municipalities with adjusted distribution
- Dosene til de fem kommunene som prioriteres tas fra 328 andre kommuner
- Primærhelsetjenesten mottar 20% av tilgjengelige doser hver uke frem til fullvaksinering. Spesialisthelsetjenesten mottar omtrent 40.000 doser i måneden frem til fullvaksinering
- Long-term stock of the different types of vaccine :
 - Pfizer: 10 000 doses
 - Moderna: 50% of doses held back for dose 2
 - AstraZeneca: 1 000 doses
 - J&J: everything sent out
 - Curevax: 10 000 doses
 - Novavax: 10 000 doses